ESMO 2020 | ISG/OS-2 trial: amending treatment of methotrexate for non metastatic osteosarcoma

Emanuela Palmerini, MD, Rizzoli Orthopedic Institute, Bologna, Italy, discusses the ISG/OS-2 (NCT01459484) trial investigating survival in patients with non-metastatic osteosarcoma treated with different chemotherapy protocols. During the study, the number of cycles of methotrexate had to be amended from 6 cycles to 10. Post-amendment survival was 89.9% after 3 years compared to 78% survival for 6 cycles. The conclusions of the study are that the number of cycles is fundamental for treatment and that 10 cycles of methotrexate should be used to treat non-metastatic osteosarcoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).